GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » EV-to-FCF

Wuhan YZY Biopharma Co (HKSE:02496) EV-to-FCF : (As of Jun. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Wuhan YZY Biopharma Co's Enterprise Value is HK$1,327.09 Mil. Wuhan YZY Biopharma Co does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Wuhan YZY Biopharma Co's EV-to-FCF at this moment.

The historical rank and industry rank for Wuhan YZY Biopharma Co's EV-to-FCF or its related term are showing as below:

HKSE:02496' s EV-to-FCF Range Over the Past 10 Years
Min: -15.15   Med: 0   Max: 0
Current: -6.46

HKSE:02496's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.31 vs HKSE:02496: -6.46

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Wuhan YZY Biopharma Co's stock price is HK$7.45. Wuhan YZY Biopharma Co does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Wuhan YZY Biopharma Co's PE Ratio at this moment.


Wuhan YZY Biopharma Co EV-to-FCF Historical Data

The historical data trend for Wuhan YZY Biopharma Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co EV-to-FCF Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
- - -7.83

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Dec23
EV-to-FCF - - -7.83

Competitive Comparison of Wuhan YZY Biopharma Co's EV-to-FCF

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan YZY Biopharma Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's EV-to-FCF falls into.



Wuhan YZY Biopharma Co EV-to-FCF Calculation

Wuhan YZY Biopharma Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1327.088/
=


Wuhan YZY Biopharma Co  (HKSE:02496) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Wuhan YZY Biopharma Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.45/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Wuhan YZY Biopharma Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan YZY Biopharma Co (HKSE:02496) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.
Executives
Dragon Merit Holdings Limited 2201 Interest of corporation controlled by you
Robust Sun Holdings Limited 2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si 2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie 2201 Interest of corporation controlled by you
Wu Shangzhi 2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co (HKSE:02496) Headlines

No Headlines